Cargando…
Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial
This multinational, randomized, double-blind trial, (ClinicalTrials.gov identifier NCT02149121) was designed to demonstrate equivalence in pharmacokinetics and efficacy between CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA). Adults with active RA were treated with CT...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152436/ https://www.ncbi.nlm.nih.gov/pubmed/30010481 http://dx.doi.org/10.1080/19420862.2018.1487912 |
_version_ | 1783357366493773824 |
---|---|
author | Park, Won Božić-Majstorović, Ljubinka Milakovic, Dragana Berrocal Kasay, Alfredo El-Khouri, Elias Chalouhi Irazoque-Palazuelos, Fedra Molina, Francisco Fidencio Cons Shesternya, Pavel Miranda, Pedro Medina-Rodriguez, Francisco G. Wiland, Piotr Jeka, Slawomir Chavez-Corrales, Jose Garmish, Olena Linde, Thomas Rekalov, Dmytro Hrycaj, Pawel Krause, Andreas Fomina, Natalia Piura, Olena Abello-Banfi, Mauricio Suh, Chang-Hee Shim, Seung Cheol Lee, Sang Joon Lee, Sung Young Kim, Sung Hwan Yoo, Dae Hyun |
author_facet | Park, Won Božić-Majstorović, Ljubinka Milakovic, Dragana Berrocal Kasay, Alfredo El-Khouri, Elias Chalouhi Irazoque-Palazuelos, Fedra Molina, Francisco Fidencio Cons Shesternya, Pavel Miranda, Pedro Medina-Rodriguez, Francisco G. Wiland, Piotr Jeka, Slawomir Chavez-Corrales, Jose Garmish, Olena Linde, Thomas Rekalov, Dmytro Hrycaj, Pawel Krause, Andreas Fomina, Natalia Piura, Olena Abello-Banfi, Mauricio Suh, Chang-Hee Shim, Seung Cheol Lee, Sang Joon Lee, Sung Young Kim, Sung Hwan Yoo, Dae Hyun |
author_sort | Park, Won |
collection | PubMed |
description | This multinational, randomized, double-blind trial, (ClinicalTrials.gov identifier NCT02149121) was designed to demonstrate equivalence in pharmacokinetics and efficacy between CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA). Adults with active RA were treated with CT-P10, United States-sourced RTX (US-RTX; Rituxan®), or European Union-sourced RTX (EU-RTX; MabThera®) at weeks 0 and 2. The co-primary pharmacokinetic endpoints were area under the serum concentration–time curve (AUC) from time zero to last measurable concentration (AUC(0–last)), AUC from time zero to infinity (AUC(0–∞)), and maximum concentration (C(max)) after two infusions. The primary efficacy endpoint was change from baseline to week 24 in Disease Activity Score using 28 joints-C-reactive protein (DAS28-CRP). Pharmacodynamics, immunogenicity, and safety were also assessed. 372 patients were randomly assigned to CT-P10 (n = 161) or RTX (n = 211 [US-RTX, n = 151; EU-RTX, n = 60]). For the co-primary pharmacokinetic endpoints, 90% confidence intervals (CI) for ratios of geometric means (CT-P10/US-RTX, CT-P10/EU-RTX or EU-RTX/US-RTX) all fell within the equivalence margin of 80–125%. Adjusted least squares (LS) mean (standard error) change from baseline in DAS28-CRP at week 24 was −2.13 (0.175) for CT-P10 and −2.09 (0.176) for RTX. The 95% CI (−0.29, 0.21) of the estimated treatment difference between CT-P10 and RTX (−0.04) was entirely within the efficacy equivalence margin of ±0.5. Pharmacodynamics, immunogenicity, and safety profiles were similar for CT-P10 and RTX. The pharmacokinetics of CT-P10, US-RTX, and EU-RTX were equivalent. CT-P10 and RTX were also equivalent in terms of efficacy and displayed similar pharmacodynamic, immunogenicity, and safety profiles up to week 24. |
format | Online Article Text |
id | pubmed-6152436 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-61524362018-09-26 Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial Park, Won Božić-Majstorović, Ljubinka Milakovic, Dragana Berrocal Kasay, Alfredo El-Khouri, Elias Chalouhi Irazoque-Palazuelos, Fedra Molina, Francisco Fidencio Cons Shesternya, Pavel Miranda, Pedro Medina-Rodriguez, Francisco G. Wiland, Piotr Jeka, Slawomir Chavez-Corrales, Jose Garmish, Olena Linde, Thomas Rekalov, Dmytro Hrycaj, Pawel Krause, Andreas Fomina, Natalia Piura, Olena Abello-Banfi, Mauricio Suh, Chang-Hee Shim, Seung Cheol Lee, Sang Joon Lee, Sung Young Kim, Sung Hwan Yoo, Dae Hyun MAbs Report This multinational, randomized, double-blind trial, (ClinicalTrials.gov identifier NCT02149121) was designed to demonstrate equivalence in pharmacokinetics and efficacy between CT-P10 and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA). Adults with active RA were treated with CT-P10, United States-sourced RTX (US-RTX; Rituxan®), or European Union-sourced RTX (EU-RTX; MabThera®) at weeks 0 and 2. The co-primary pharmacokinetic endpoints were area under the serum concentration–time curve (AUC) from time zero to last measurable concentration (AUC(0–last)), AUC from time zero to infinity (AUC(0–∞)), and maximum concentration (C(max)) after two infusions. The primary efficacy endpoint was change from baseline to week 24 in Disease Activity Score using 28 joints-C-reactive protein (DAS28-CRP). Pharmacodynamics, immunogenicity, and safety were also assessed. 372 patients were randomly assigned to CT-P10 (n = 161) or RTX (n = 211 [US-RTX, n = 151; EU-RTX, n = 60]). For the co-primary pharmacokinetic endpoints, 90% confidence intervals (CI) for ratios of geometric means (CT-P10/US-RTX, CT-P10/EU-RTX or EU-RTX/US-RTX) all fell within the equivalence margin of 80–125%. Adjusted least squares (LS) mean (standard error) change from baseline in DAS28-CRP at week 24 was −2.13 (0.175) for CT-P10 and −2.09 (0.176) for RTX. The 95% CI (−0.29, 0.21) of the estimated treatment difference between CT-P10 and RTX (−0.04) was entirely within the efficacy equivalence margin of ±0.5. Pharmacodynamics, immunogenicity, and safety profiles were similar for CT-P10 and RTX. The pharmacokinetics of CT-P10, US-RTX, and EU-RTX were equivalent. CT-P10 and RTX were also equivalent in terms of efficacy and displayed similar pharmacodynamic, immunogenicity, and safety profiles up to week 24. Taylor & Francis 2018-07-16 /pmc/articles/PMC6152436/ /pubmed/30010481 http://dx.doi.org/10.1080/19420862.2018.1487912 Text en © 2018 The Author(s). Published with license by Taylor & Francis. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Report Park, Won Božić-Majstorović, Ljubinka Milakovic, Dragana Berrocal Kasay, Alfredo El-Khouri, Elias Chalouhi Irazoque-Palazuelos, Fedra Molina, Francisco Fidencio Cons Shesternya, Pavel Miranda, Pedro Medina-Rodriguez, Francisco G. Wiland, Piotr Jeka, Slawomir Chavez-Corrales, Jose Garmish, Olena Linde, Thomas Rekalov, Dmytro Hrycaj, Pawel Krause, Andreas Fomina, Natalia Piura, Olena Abello-Banfi, Mauricio Suh, Chang-Hee Shim, Seung Cheol Lee, Sang Joon Lee, Sung Young Kim, Sung Hwan Yoo, Dae Hyun Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title_full | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title_fullStr | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title_full_unstemmed | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title_short | Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial |
title_sort | comparison of biosimilar ct-p10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled phase 3 trial |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152436/ https://www.ncbi.nlm.nih.gov/pubmed/30010481 http://dx.doi.org/10.1080/19420862.2018.1487912 |
work_keys_str_mv | AT parkwon comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT bozicmajstorovicljubinka comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT milakovicdragana comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT berrocalkasayalfredo comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT elkhourieliaschalouhi comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT irazoquepalazuelosfedra comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT molinafranciscofidenciocons comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT shesternyapavel comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT mirandapedro comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT medinarodriguezfranciscog comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT wilandpiotr comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT jekaslawomir comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT chavezcorralesjose comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT garmisholena comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT lindethomas comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT rekalovdmytro comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT hrycajpawel comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT krauseandreas comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT fominanatalia comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT piuraolena comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT abellobanfimauricio comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT suhchanghee comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT shimseungcheol comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT leesangjoon comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT leesungyoung comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT kimsunghwan comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial AT yoodaehyun comparisonofbiosimilarctp10andinnovatorrituximabinpatientswithrheumatoidarthritisarandomizedcontrolledphase3trial |